Bausch Health Companies Inc. BHC
Nov 3, 2026, 3:40 PM EST
- YTD
- +15.97%
- 1 year
- +18.36%
- Market cap
- 3.02B
- Revenue (ttm)
- 11.11B
- Profit margin
- -7.57%
- EPS (ttm)
- -2.26
- Shares out
- 374.27M
- Forward P/E
- 1.85
- YTD return
- +15.97%
- 1-year return
- +18.36%
- Volume
- 2.30M
- Avg volume
- 3.29M
- Open
- 7.96
- Previous close
- 8.02
- Day's range
- 7.87 – 8.13
- 52-week range
- 4.33 – 9.04
- Beta
- 0.28
- Analysts
- Hold
- Price target
- 8.00 (-0.7%)
- Earnings date
- Feb 17, 2027
1m +0.04 (+0.50%)
Key statistics
- Enterprise value
- 22.29B
- PEG ratio
- 0.01
- Price / sales
- 0.27
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 9.70%
- Free cash flow
- 1.64B
- Total cash
- 2.48B
- Total debt
- 20.71B
- Return on equity
- -11040.00%
- Short % of float
- 2.75%
- 50-day average
- 6.24
- 200-day average
- 5.70
Analyst view
Consensus: hold
- Target (low)
- 7.00
- Target (mean)
- 8.00
- Target (high)
- 10.00
- Strong buy0
- Buy0
- Hold7
- Sell0
- Strong sell0
Next earnings
Feb 17, 2027
Expected Feb 17, 2027. Consensus EPS estimate 1.32.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 17, 2027 | Dec 30, 2026 | 1.35 | — | — | — |
| Oct 28, 2026 | Sep 30, 2026 | 1.25 | 1.77 | +0.52 | +41.60% |
| Jul 29, 2026 | Jun 30, 2026 | 0.96 | 1.26 | +0.30 | +31.25% |
| Apr 29, 2026 | Mar 31, 2026 | 0.81 | 0.78 | -0.03 | -3.70% |
| Feb 18, 2026 | Dec 31, 2025 | 1.21 | 1.08 | -0.13 | -10.74% |
| Oct 29, 2025 | Sep 30, 2025 | 1.07 | 1.16 | +0.09 | +8.41% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 29, 2026 | Jefferies | main | Hold | Hold |
| Oct 29, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Apr 27, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Feb 25, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
| Jan 7, 2026 | Truist Securities | main | Hold | Hold |
| Dec 9, 2025 | Barclays | init | — | Equal-Weight |
About Bausch Health Companies Inc.
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, Czech Republic, Slovakia, Ukraine, Bulgaria, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Canada
- Website
- bauschhealth.com
News
Is Bausch Health (BHC) Stock Outpacing Its Medical Peers This Year? 
Jefferies Maintains Hold on Bausch Health Companies, Raises Price Target to $8 
RBC Capital Maintains Sector Perform on Bausch Health Companies, Raises Price Target to $10 
12 Health Care Stocks Moving In Thursday's Intraday Session 
BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook Rises 
Huntington Ingalls, Crocs, Carvana, Insmed And Other Big Stocks Moving Higher On Thursday 
Bausch Health Companies Inc. (BHC) Q3 2026 Earnings Call Transcript 
Bausch (BHC) Reports Q3 Earnings: What Key Metrics Have to Say 
Bausch Health (BHC) Surpasses Q3 Earnings and Revenue Estimates 
What Bausch Health Cos (BHC) Said on Its Q3 Earnings Call
Your note
Sign in to keep a note on BHC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| APPIO THOMAS J | Chief Executive Officer | Stock Award(Grant) | Feb 24, 2026 | 3,620,030 |
| CARSON SEANA LYNNE | General Counsel | Sale | Mar 2, 2026 | 616,761 |
| CHARHON JEAN-JACQUES | Chief Financial Officer | Stock Award(Grant) | Feb 24, 2026 | 755,538 |
| KAVANAGH SARAH BALDWIN | Director | Stock Award(Grant) | May 21, 2026 | 282,230 |
| LENAR AIMEE J | Officer | Sale | Aug 18, 2026 | 334,853 |
| MILLER STEVEN D | Director | Stock Award(Grant) | May 15, 2025 | 239,224 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| PAULSON & CO. INC. | 19.57% | 73,255,869 | 588.24M | Jun 29, 2026 |
| Goldentree Asset Management LP | 9.26% | 34,665,731 | 278.37M | Jun 29, 2026 |
| Royal Bank of Canada | 2.89% | 10,832,582 | 86.99M | Jun 29, 2026 |
| Healthcare of Ontario Pension Plan Trust Fund | 2.14% | 8,000,000 | 64.24M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 1.99% | 7,465,468 | 59.95M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 1.66% | 6,225,131 | 49.99M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund | 1.01% | 3,762,192 | 30.21M | Jul 30, 2026 |
| VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund | 0.66% | 2,481,313 | 19.92M | Jun 29, 2026 |
| SCHWAB STRATEGIC TRUST-Schwab Fundamental International Equity ETF | 0.43% | 1,617,412 | 12.99M | Aug 30, 2026 |
| VANGUARD Intl Eqy. INDEX Fd.S-Vanguard FTSE All-World ex-US Small-Cap | 0.26% | 986,066 | 7.92M | Jul 30, 2026 |
| DFA INVESTMENT TRUST CO-The Canadian Small Company Series | 0.22% | 815,010 | 6.54M | Jul 30, 2026 |
| DFA INVESTMENT DIMENSIONS GROUP INC-Intl Core Eqy. 2 PORT. | 0.16% | 594,511 | 4.77M | Jul 30, 2026 |